Article
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.
Clinical lung cancer - 1 Jul 2018
Wu Yi-Long, Herbst Roy S, Mann Helen, Rukazenkov Yuri, Marotti Marcelo, Tsuboi Masahiro
Abstract excerpt
INTRODUCTION: Currently, the role of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as adjuvant therapy for early-stage non-small-cell lung cancer after complete surgical tumor resection remains under investigation. We present the rationale and study design for the ADAURA (ClinicalTrials.gov identifier, NCT02511106) trial, a multicenter, double-blind, randomized, placebo-controlled study....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.